vorinostat has been researched along with Neoplasms, Pleural in 7 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, F | 1 |
| Ahmad, M | 1 |
| Qayyum, F | 1 |
| Straus, CM | 1 |
| MacMahon, H | 1 |
| Kindler, H | 1 |
| Armato, SG | 1 |
| Crawford, N | 1 |
| Stasik, I | 2 |
| Holohan, C | 2 |
| Majkut, J | 1 |
| McGrath, M | 1 |
| Johnston, PG | 2 |
| Chessari, G | 1 |
| Ward, GA | 1 |
| Waugh, DJ | 1 |
| Fennell, DA | 2 |
| Longley, DB | 2 |
| Yamamoto, K | 1 |
| Seike, M | 1 |
| Takeuchi, S | 1 |
| Soeno, C | 1 |
| Miyanaga, A | 1 |
| Noro, R | 1 |
| Minegishi, Y | 1 |
| Kubota, K | 1 |
| Gemma, A | 1 |
| Paik, PK | 1 |
| Krug, LM | 2 |
| Leclercq, S | 1 |
| Gueugnon, F | 1 |
| Boutin, B | 1 |
| Guillot, F | 1 |
| Blanquart, C | 1 |
| Rogel, A | 1 |
| Padieu, M | 1 |
| Pouliquen, D | 1 |
| Fonteneau, JF | 1 |
| Grégoire, M | 1 |
| Hurwitz, JL | 1 |
| Kerr, EM | 1 |
| Redmond, KM | 1 |
| McLaughlin, KM | 1 |
| Busacca, S | 1 |
| Barbone, D | 1 |
| Broaddus, VC | 1 |
| Gray, SG | 1 |
| O'Byrne, KJ | 1 |
| Curley, T | 1 |
| Schwartz, L | 1 |
| Richardson, S | 1 |
| Marks, P | 1 |
| Chiao, J | 1 |
| Kelly, WK | 1 |
1 review available for vorinostat and Neoplasms, Pleural
| Article | Year |
|---|---|
Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation; Drug Evaluation, Preclini | 2010 |
2 trials available for vorinostat and Neoplasms, Pleural
| Article | Year |
|---|---|
Correlation of patient survival with clinical tumor measurements in malignant pleural mesothelioma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Illinois; Lung Neoplasms; Male; Meso | 2019 |
Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid.
Topics: Administration, Oral; Adult; Aged; Cohort Studies; Drug Administration Schedule; Enzyme Inhibitors; | 2006 |
4 other studies available for vorinostat and Neoplasms, Pleural
| Article | Year |
|---|---|
SAHA overcomes FLIP-mediated inhibition of SMAC mimetic-induced apoptosis in mesothelioma.
Topics: Antineoplastic Agents; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 3; Caspase 8; Cell | 2013 |
MiR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Express | 2014 |
A 5-aza-2'-deoxycytidine/valproate combination induces cytotoxic T-cell response against mesothelioma.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line, | 2011 |
Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent.
Topics: Apoptosis; Apoptosis Regulatory Proteins; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase | 2012 |